Kirchner Group Advises Investor in $700M Financing in the BioTech Sector
Kirchner Group is pleased to announce that it acted as an advisor on due diligence to the Alaska Permanent Fund (represented by Crestline Investors) in the recently announced Sana Biotechnology $700M initial financing.
26 June 2020 – Kirchner Group is pleased to announce that it acted as an advisor on due diligence to the Alaska Permanent Fund (represented by Crestline Investors) in the recently announced Sana Biotechnology $700M initial financing.
According to the announcement Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. They share a vision of repairing and controlling genes, replacing missing or damaged cells, and making their therapies broadly available to patients. Their team consists of 200 plus scientists, engineers, clinicians and biotechnology veterans creating an enduring company that makes meaningful medicines and changes how we approach treating disease. Sana has operations in Seattle, Cambridge, and South San Francisco.
“It is an honor to be the go to group to assist numerous investors in highly technical and scientific diligence for groundbreaking companies like Sana,” stated Blair Kirchner, Managing Director of Kirchner Group. “Our network and unique platform enable us to provide rapid and insightful input to investors around the world.”
Kirchner Group is also proud to note their previous similar roles in the Denali Therapeutics (NASDAQ: DNLI), Juno Therapeutics (acquired by Celgene for approx. $9B) and Indigo Agriculture financings.